Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

1.

Phase II cancer prevention clinical trials.

Szabo E.

Semin Oncol. 2010 Aug;37(4):359-66. doi: 10.1053/j.seminoncol.2010.06.015. Review.

PMID:
20816506
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.

[No authors listed]

Drugs R D. 2007;8(2):103-12. Review.

PMID:
17324008
[PubMed - indexed for MEDLINE]
3.

Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.

Lieberman R.

Urology. 2001 Apr;57(4 Suppl 1):224-9.

PMID:
11295633
[PubMed - indexed for MEDLINE]
4.

Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.

Kelloff GJ, Boone CW, Crowell JA, Nayfield SG, Hawk E, Steele VE, Lubet RA, Sigman CC.

J Cell Biochem Suppl. 1995;23:1-9. Review.

PMID:
8747372
[PubMed - indexed for MEDLINE]
5.

The clinical evaluation of cancer prevention agents.

Goodman GE.

Proc Soc Exp Biol Med. 1997 Nov;216(2):253-9. Review.

PMID:
9349694
[PubMed - indexed for MEDLINE]
6.

Bleomycin--electrical pulse delivery: electroporation therapy-bleomycin--Genetronics; MedPulser-bleomycin--Genetronics.

[No authors listed]

Drugs R D. 2004;5(5):293-6.

PMID:
15357628
[PubMed - indexed for MEDLINE]
7.

Phase II clinical trials in oncology: are we hitting the target?

Ang MK, Tan SB, Lim WT.

Expert Rev Anticancer Ther. 2010 Mar;10(3):427-38. doi: 10.1586/era.09.178. Review.

PMID:
20214523
[PubMed - indexed for MEDLINE]
8.

Surrogate endpoint biomarkers for phase II cancer chemoprevention trials.

Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet R, Doody LA.

J Cell Biochem Suppl. 1994;19:1-9. Review.

PMID:
7823579
[PubMed - indexed for MEDLINE]
9.

Design issues of randomized phase II trials and a proposal for phase II screening trials.

Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA.

J Clin Oncol. 2005 Oct 1;23(28):7199-206.

PMID:
16192604
[PubMed - indexed for MEDLINE]
Free Article
10.

Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.

Greenwald P.

J Cell Biochem Suppl. 1996;25:29-36. Review.

PMID:
9027595
[PubMed - indexed for MEDLINE]
11.

Alternate endpoints for screening phase II studies.

Dhani N, Tu D, Sargent DJ, Seymour L, Moore MJ.

Clin Cancer Res. 2009 Mar 15;15(6):1873-82. doi: 10.1158/1078-0432.CCR-08-2034. Epub 2009 Mar 10. Review.

PMID:
19276273
[PubMed - indexed for MEDLINE]
Free Article
12.

Risk biomarkers and current strategies for cancer chemoprevention.

Kelloff GJ, Boone CW, Crowell JA, Nayfield SG, Hawk E, Malone WF, Steele VE, Lubet RA, Sigman CC.

J Cell Biochem Suppl. 1996;25:1-14. Review.

PMID:
9027592
[PubMed - indexed for MEDLINE]
13.

The phase II/III transition. Toward the proof of efficacy in cancer clinical trials.

Fazzari M, Heller G, Scher HI.

Control Clin Trials. 2000 Aug;21(4):360-8.

PMID:
10913810
[PubMed - indexed for MEDLINE]
14.

Clinical trial design in metastatic breast cancer: a commentary.

Levine M.

Can J Oncol. 1995 Dec;5 Suppl 1:40-2.

PMID:
8853523
[PubMed - indexed for MEDLINE]
15.

Bayesian monitoring of phase II trials in cancer chemoprevention.

Cronin KA, Freedman LS, Lieberman R, Weiss HL, Beenken SW, Kelloff GJ.

J Clin Epidemiol. 1999 Aug;52(8):705-11.

PMID:
10465313
[PubMed - indexed for MEDLINE]
16.

Targeting population entering phase III trials: a new stratified adaptive phase II design.

Tournoux-Facon C, De Rycke Y, Tubert-Bitter P.

Stat Med. 2011 Apr 15;30(8):801-11. doi: 10.1002/sim.4148. Epub 2011 Jan 12.

PMID:
21432875
[PubMed - indexed for MEDLINE]
17.

Optimal and minimax three-stage designs for phase II oncology clinical trials.

Chen K, Shan M.

Contemp Clin Trials. 2008 Jan;29(1):32-41. Epub 2007 May 6.

PMID:
17544337
[PubMed - indexed for MEDLINE]
18.

Randomized phase II designs in cancer clinical trials: current status and future directions.

Lee JJ, Feng L.

J Clin Oncol. 2005 Jul 1;23(19):4450-7. Review.

PMID:
15994154
[PubMed - indexed for MEDLINE]
Free Article
19.

Development of breast cancer chemopreventive drugs.

Kelloff GJ, Boone CW, Steele VE, Crowell JA, Lubet R, Doody LA, Greenwald P.

J Cell Biochem Suppl. 1993;17G:2-13. Review.

PMID:
8007699
[PubMed - indexed for MEDLINE]
20.

Designing a randomized phase I/II prostate cancer chemoprevention trial using 1alpha-hydroxy-24-ethyl-cholecalciferol, an analogue of vitamin D3.

Packianathan S, Mehta RG, Mehta RR, Hall WH, Boerner PS, Beckett LA, Vijayakumar S.

Cancer J. 2004 Nov-Dec;10(6):357-67.

PMID:
15701267
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk